Зуд при атопическом дерматите: от этиологических особенностей к терапевтической тактике

Одним из основных клинических проявлений атопического дерматита является зуд, значительно ухудшающий качество жизни пациентов в детском возрасте. Научные представления о его патофизиологической основе в настоящее время претерпели серьезные изменения. В том числе опровергнута исключительная роль гистамина в развитии зуда, а также приведены сведения об участии иммунной системы в его поддержании. В статье представлены современные данные о дифференциальных подходах к терапии зуда в зависимости от его этиопатогенетических характеристик. Уделено внимание значимости дерматокосметики в восстановлении кожного барьера как первой ступени в профилактике зуда при атопическом дерматите. Представлены результаты клинических исследований, свидетельствующие об эффективности применения топических средств на основе инновационного компонента с противозудным действием STIMU-TEX.

1. Mollanazar NK, Koch SD, Yosipovitch G. Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going? Curr Derm Rep. 2015;4:20–29. doi: 10.1007/s13671-014-0093-y.

2. Blome C, Radtke MA, Eissing L, Augustin M. Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. Am J Clin Dermatol, 2016;17(2):163–169. doi: 10.1007/s40257-015-0171-3.

3. Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.

4. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 2001;4(1):9–10. doi: 10.1038/82924.

5. Chuquilin M, Alghalith Y, Fernandez KH. Neurocutaneous disease. J Am Acad Dermatol. 2016;74(2):197–212. doi: 10.1016/j.jaad.2015.04.060.

6. Адаскевич В.П. Кожный зуд. Дерматологический и междисциплинарный феномен. М.: БИНОМ; 2014. 260 с.

7. B ieber T, Leung DYM. Atopic Dermatitis. CRC Press; 2002. p. 49.

8. Verze L, Carla V-P, Maurizo S, et al. Distribution of GAP-43 nerve fibers in the skin of the adult human hand. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology. Anat Rec A Discov Mol Cell Evol Biol. 2003;272A(1):467–473. doi: 10.1002/ar.a.10056.

9. Abbracchio MP, Reggiani AM. Pain and nociception. In: Galizia CG, Lledo P-M, eds. Neurosciencesefrom molecule to behavior: a university textbook. 2nd ed. Berlin, Germany: Springer Berlin Heidelberg; 2013. pp. 455–459.

10. Roosterman D, Goerge T, Schneider SW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–1379. doi: 10.1152/physrev.00026.2005.

11. Lawson SN. Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Alpha/beta-fibres. Exp Physiol. 2002;87(2):239–244.

12. Elder D. Histology of the skin. In: Elder D, ed. Lever’s histopathology of the skin. 9th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2005.

13. Myers MI, Peltier AC, Li J. Evaluating dermal myelinated nerve fibers in skin biopsy. Muscle Nerve. 2013;47(1):1–11. doi: 10.1002/mus.23510

14. Thestrup-Pedersen К. Clinical aspects of atopic dermatitis. Clin Ехр Dernatol. 2000;25(7):535–543. doi: 10.1046/j.1365-2230.2000.00696.x.

15. Krause L, Shuster S. Mechanisms of action of antipruritic drugs. Br Med J (Clin Res Ed). 1983;287(6400):1199–1200. doi: 10.1136/bmj.287.6400.1199.

16. Greaves МW. Antihistamines. Dermatol Clin. 2001;19(1): 53–62. doi: 10.1016/s0733-8635(05)70229-1.

17. Rukwied R, Неуеr C. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylholine in atopic eczema patients and healthy controls. Аrсh Dermatol Res. 1998;290(4):198–204. doi: 10.1007/s004030050290.

18. Vogelsang М, Heyer С, Hornstein ОР. Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Acta Derm Venereol. 1995;75(6):434–436. doi: 10.2340/0001555575434436.

19. Heyer С, Vogelsang М, Hornstein ОР. Acetylholine is аn inducer of itching in patients with atopic eczema. J Dermatol. 1997;24(10): 621–625. doi: 10.1111/j.1346-8138.1997.tb02305.x.

20. Ikoma А, Fartasch М, Неуеr Р, et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology. 2004;62(2):212–217. doi: 10.1212/wnl.62.2.212.

21. Steinhoff М, Vergnolle N, Young SH, et аl. Agonists of proteinase activated receptor 2 induce inflammation bу а nеurogenic mechanism. Nat Med. 2000;6(2):151–158. doi: 10.1038/72247.

22. Di Marzo V, Blumberg РМ, Szallasi А. Endovanilloid signalling in pain. Curr Opin Neurobiol. 2002;12(4):372–379. doi: 10.1016/s0959-4388(02)00340-9.

23. Caterina МJ, Julius D. Тhе vanilloid receptor а mоlесulаr gateway to the pain pathway. Аnn Rev Neurosci. 2001;24:487–517. doi: 10.1146/annurev.neuro.24.1.487.

24. Stander S, Luger Т, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Аm Acad Dermato. 2001;44(3):471–478. doi: 10.1067/mjd.2001.110059.

25. Stander S, Luger ТА. Antipruritic effects of pimecrolimus and tacroli mus. Haurtarzt. 2003;54(5):413–414. doi: 10.1007/s00105-003-0521-6.

26. Dvorak М, Watkinson А. McClone Р, Rulwied R. Histamine induced responses аrе attenuated by а cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52(6):238–245. doi: 10.1007/s00011-003-1162-z.

27. Kеmеnу L. Comparative study of S235 сrеаm and hydrocortisone 1% in patients with atopic dermatitis. J Аm Acad Dermatol. 2006;52(3 Supрl):P68. doi: 10.1016/j.jaad.2004.10.282.

28. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain. 1997; 71(1):49–55. doi: 10.1016/s0304-3959(97)03339-3.

29. Fjellner В, Hagermark O. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol. 1984; 64(1):73–75.

30. Kо МG, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology. 2000;92(3):795–805. doi: 10.1097/00000542-200003000-00023.

31. Patel T, Yosipovitch G. Therapy of pruritus. Exp Opin Pharmacother. 2010;11(10):1673–1682. doi: 10.1517/14656566.2010.484420.

32. Elmariah SB, Lerner EA. Topical Therapies for Pruritus. Semin Cutan Med Surg. 2011;30(2):118–126. doi: 10.1016/j.sder.2011.04.008.

33. Dillon SR, Sprecher C, Bilsborough J, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–760. doi: 10.1038/ni1084.

34. Bilsborough J, Leung DY, Маuer М, et al. IL-31 is associated with. Cutaneous lymphocyte antigen-positive skin homing Т cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006; 117(2):418–425. doi: 10.1016/j.jaci.2005.10.046.

35. Jоhnаnssоn О, Liang Y, Marcusson JА, Reimert СМ. Eosinophil cationic protein- and eosinophil-derived nеurоtохin/ еosinophil protein Х-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292(8):371–378. doi: 10.1007/s004030000142.

36. Kapp А. The role of еosinophil in раthоgеnеsis of atopic dermatitis — еosinophil granule proteins as markers of disease activity. Allergy. 1993;48(1):1–5. doi: 10.1111/j.1398-9995.1993.tb02167.x.

37. Raap U, Goltz С, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosiniophil functions compared with that seen in non-atopic subjects. J Allergy Clin Immunol. 2005;115(6):1268–1275. doi: 10.1016/j.jaci.2005.02.007.

38. Raap U, Werfel Т, Goltz С, et аl. Circulating levels of brain-derived neurotrophic factor correlates with disease severity in the intrinsic type of atopic dermatitis. Allergy. 2006;61(12):1416–1418. doi: 10.1111/j.1398-9995.2006.01210.x.

39. Raap U, Kapp А. Neuroimmunological findings in allergic skin diseases. Сurr Opin Allergy Clin Immunol. 2005;5(5):419–424. doi: 10.1097/01.all.0000183111.78558.4d.

40. Remrod С, Lonne-Rahm S, Nordlind К. Study of substance Р аnd its receptor neurokinin-l in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res. 2007;299(2):85–91. doi: 10.1007/s00403-007-0745-x.

41. Huang YJ, Marsland BJ, Bunyavanich S, et al. The microbiome in allergic disease: Current understanding and future opportunities — 2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4): 1099–1110. doi: 10.1016/j.jaci.2017.02.007.

42. Engebretsen KA, Linneberg A, Thuesen BH, et al. Xerosis is associated with asthma in men independent of atopic dermatitis and filaggrin gene mutations. J Eur Acad Dermatol Venereol. 2015; 29(9):1807–1815. doi: 10.1111/jdv.13051.

43. Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: 10.1016/j.jaci.2012.12.1566.

44. Howell MD, Kim BE, Boguniewicz M, Leung DYM. Modulation of filaggrin by Th2 cytokines in the skin of Atopic Dermatitis (AD). J Allergy Clin Immunol. 2007;119(1):S283.

45. N orman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther. 2003;16(3):254–259. doi: 10.1046/j.1529-8019.2003.01635.x.

46. Fjellner В, Arnetz ВВ. Psychological predictors of pruritus during mental stress. Acta Dermatol Venereol. 1985;65(6):504–508.

47. Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992;47(2 Pt 1):65–75. doi: 10.1111/j.1398-9995.1992.tb05091.x.

48. Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т. 15. — № 3. — С. 279–293. doi: 10.15690/vsp.v15i3.1566.

49. Yvette A. Tivoli, DO, Rubenstein RM. Pruritus. J Clin Aesthet Dermatol. 2009;2(7):30–36.

50. Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т. и др. Дерма то логические аспекты зуда // Педиатрия (Прил. к журн. Consilium Medicum). — 2018. — № 1. — С. 121–125. doi: 10.26442/2413-8460_2018.1.121-125.

51. Reunala T, Salmi TT, Hervonen K, et al. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018;10(5):602. doi: 10.3390/nu10050602.

52. Kulczycka-Siennicka L, Cynkier A, Waszczykowska E, et al. The Role of Intereukin-31 in Pathogenesis of Itch and Its Intensity in a Course of Bullous Pemphigoid and Dermatitis Herpetiformis. Biomed Res Int. 2017;2017:5965492. doi: 10.1155/2017/5965492.

53. Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of Itch in Atopic Dermatitis. Semin Cutan Med Surg. 2011;30(2): 71–86. doi: 10.1016/j.sder.2011.05.002.

54. Bock SA. The natural history of food sensitivity. J Allergy Clin Immunol. 1982;69(2):173–117. doi: 10.1016/0091-6749(82)90096-3.

55. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibo dies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993; 92(3):1374–1380. doi: 10.1172/JCI116711.

56. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: 10.1016/j.jaci.2008.01.022.

57. Vilaplana J, Coll J, Trullas C, et al: Clinical and non-invasive evaluation of 12% ammonium lactate emulsion for the treatment of dry skin in atopic and non-atopic subjects. Acta Derm Venereol. 1992;72(1):28–33.

58. Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57(5):873–878. doi: 10.1016/j.jaad.2007.04.008.

59. Summey BT, Jr, Yosipovich G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther. 2005;18(4):328–332. doi: 10.1111/j.1529-8019.2005.00035.x.

60. Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy. 2010;65(7):805–821. doi: 10.1111/j.1398-9995.2010.01995.x.

61. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol. 1990; 70(4):323–329.

62. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338(8760):137–140. doi: 10.1016/0140-6736(91)90134-b.

63. Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther. 2005;18(4):344–354. doi: 10.1111/j.1529-8019.2005.00032.x.

64. Gupta MA, Gupta AK, Schork NJ, et al. Depression modulates pruritus perception: A study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994; 56(1):36–40. doi: 10.1097/00006842-199401000-00005.

65. Wang F-P, Tang X-J, Wei C-Q, et al. Dupilumab treatment in mode rate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198. doi: 10.1016/j.jdermsci.2018.01.016.

66. Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142:1121–1130.e7. doi: 10.1016/j.jaci.2018.03.018.

67. Yosipovitch G, Rosen JD, Hashimoto Ti. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018; 142(5):1375–1390. doi: 10.1016/j.jaci.2018.09.005.

68. Fukuyama T, Ganchingco JR, Mishra SK, et al. Janus kinase inhibitors display broad anti-itch properties: a possible link through the TRPV1 receptor. J Allergy Clin Immunol. 2017;140(1):306–309. e3. doi: 10.1016/j.jaci.2016.12.960.

69. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course — a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998. doi: 10.1111/j.1610-0387.2010.07497.x.

70. Schommer A, Matthies C, Petersen I, Augustin M. Effektivitat einer Polidocanol–Harnstoff–Kombination bei trockener, juckender Haut. Ergebnisse einer methodisch gepruften Anwendungsbeobachtung. Aktuelle Dermatologie. 2007;33(01/02):33–38. doi: 10.1055/s-2006-945179.

71. Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zur Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsaure-haltigen Fettcreme. Dermatosen in Beruf und Umwelt = Occupation and environment. 1993;41(5):184–188.

72. Spoo J, Schliemann-Willers S, Elsner P. Evaluation of the antihistaminergic efficfcy of STIMU-TEX® AS on iontophoretically induced histamine irritftion by laser Doppler flowmetry. Test report. Available online: https://atopicbaby.ru/clinical_trials/stimu-tex-as-in-vivorelief-of-histamine-related-symptoms. Accessed on June 20, 2020.

73. Мигачева Н.Б., Орлов Е.В., Чаплыгина С.И. и др. Инновационные средства ухода за кожей детей с атопическим дерматитом // РМЖ. — 2017. — № 19. — С. 1391–1395.

74. Ларькова И.А., Ревякина В.А., Кравцова П.О., Кувшинова Е.Д. Современные средства ухода за кожей в базисной терапии атопического дерматита у детей // Педиатрия (Прил. к журн. Consilium Medicum). — 2017. — № 1. — 86–88.

75. Елисютина О.Г., Литовкина А.О., Феденко Е.С. Опыт использования современных средств по уходу за кожей серии Атопик® у детей с атопическим дерматитом // Российский аллергологический журнал. — 2017. — Т. 14. — №. 2. — С. 76–81.

76. Нурпеисов Т.Т., Беркинбаев С.Ф., Газалиева М.А., Хан В.В. Применение комплекса топических средств для лечения атопического дерматита у детей // Вопросы практической педиатрии. — 2017. — Т. 12. — № 5. — С. 73–77. doi: 10.20953/1817-7646-2017-5-73-77.